305 related articles for article (PubMed ID: 35498998)
21. Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns.
Chatterton DE; Nguyen DN; Bering SB; Sangild PT
Int J Biochem Cell Biol; 2013 Aug; 45(8):1730-47. PubMed ID: 23660296
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M; Stalla GK
Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
[TBL] [Abstract][Full Text] [Related]
24. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
25. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
26. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of p53 regulation of oxidative stress in skeletal muscle.
Beyfuss K; Hood DA
Redox Rep; 2018 Dec; 23(1):100-117. PubMed ID: 29298131
[TBL] [Abstract][Full Text] [Related]
28. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
29. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
30. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
31. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
[TBL] [Abstract][Full Text] [Related]
32. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes.
Fasshauer M; Klein J; Kriauciunas KM; Ueki K; Benito M; Kahn CR
Mol Cell Biol; 2001 Jan; 21(1):319-29. PubMed ID: 11113206
[TBL] [Abstract][Full Text] [Related]
33. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
34. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
Maida A; Lamont BJ; Cao X; Drucker DJ
Diabetologia; 2011 Feb; 54(2):339-49. PubMed ID: 20972533
[TBL] [Abstract][Full Text] [Related]
35. Novel insights of dietary polyphenols and obesity.
Wang S; Moustaid-Moussa N; Chen L; Mo H; Shastri A; Su R; Bapat P; Kwun I; Shen CL
J Nutr Biochem; 2014 Jan; 25(1):1-18. PubMed ID: 24314860
[TBL] [Abstract][Full Text] [Related]
36. Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human HepG2 cells.
Cordero-Herrera I; Martín MÁ; Goya L; Ramos S
Food Chem Toxicol; 2014 Feb; 64():10-9. PubMed ID: 24262486
[TBL] [Abstract][Full Text] [Related]
37. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
38. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
39. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
40. Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts.
Zhou F; Song P; Tang X; Yang Q; Zhou S; Xu R; Fang T; Jia Z; Han J
Peptides; 2022 Jul; 153():170811. PubMed ID: 35594964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
